Imunon Reports Strong Enrollment Momentum In Phase 3 Ovation 3 Trial Of Imnn-001 In Advanced Ovarian Cancer
IMNN•Phase 3 Ovation 3 enrollment momentum
July 30 (Reuters) - Imunon Inc IMNN.O:
- Imunon reports strong enrollment momentum in Phase 3 Ovation 3 trial of IMNN-001 in advanced ovarian cancer
- Imunon reports enrollment rate exceeding forecast in Ovation 3 trial
- Imunon projects enrollment completion in Q2 2029 for Ovation 3 trial
- Imunon says IMNN-001 demonstrates favorable safety profile with no serious immune-related adverse events
Related News
ENB Financial FY26 Q2 net income falls 1.8% to $5.7 million; net interest income rises 17.7% to $20.78 million
ENBP•
Clean Energy Technologies sells USD 178,410 convertible note to Pacific Pier Capital II for USD 150,000.80
CETY•
